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Tumor growth is dependent in part on interactions between tumor cells and the extracellular 
matrix of host tissues. Expression of the cell surface glycoprotein CD44/Pgp-1, which mediates 
cell-substrate  interactions is increased in many types of malignancies, but the role of CD44 in 
tumor growth is largely undefined. Recently, two isoforms of CD44 have been identified: an 
80-90 kD form, which has high affinity for cell bound hyaluronate and a 150 kD form which 
does not mediate attachment to hyaluronate-coated surfaces. In this work, human B cell lymphoma 
cells stably transfected with eDNA clones encoding either of the two CD44 isoforms were compared 
for tumorigenicity and metastatic potential in nude mice.  Expression of the 80-90 kD form 
but not the 150 kD form of CD44 greatly enhanced both local tumor formation and metastatic 
proclivity of the lymphoma cells. Our results suggest that CD44 polypeptides may play an important 
role in regulating primary and metastatic tumor development in vivo. 
T 
he cell surface proteoglycan CD44 has been shown to 
play a role in lymphocyte activation (1, 2), cell-cell adhe- 
sion (3),  and cell-substrate  interactions (4). Recently, two 
isoforms of CD44 have been identified which differ both in 
molecular mass and affinity for substrate. The first, CD44H, 
is  an  80-90  kD  glycoprotein, expressed  in cells  of both 
mesodermal and neuroectodermal origin (5, 6), and has been 
proposed to be the principal cell surface  receptor for hyaluronate 
(7, 8). The second, CD44E, is a 150-kD  species, expressed 
in a subpopulation of epithelial cells, and does not appear 
to display affinity for hyaluronate (5, 9). Isolation and char- 
acterization of eDNA clones encoding both isoforms have 
shown that the predicted proteins are identical with the ex- 
ception that the CD44E polypeptide contains an additional 
stretch of 134 amino acids intercalated between 220 and 224 
of the extracellular  domain of CD44H  (9,  10). 
The difference in affinity for surface-bound hyaluronate be- 
tween the two CD44 isoforms is likely to reflect different 
functional roles.  Hyaluronate belongs to the glycosamino- 
glycan class of molecules which participate in the assembly 
of the extracellular  matrix (ECM) 1, and is believed to play 
an important role in embryogenesis (11), wound healing (11, 
12),  and  inflammation  (13).  Increased  production  of 
hyaluronate is associated with tumor growth, possibly as a 
result of tumor-stromal cell interaction (14), and has been 
proposed to enhance tumor invasiveness (15). Expression of 
CD44 in malignant cells may therefore help regulate primary 
tumor growth, local invasiveness and metastatic proclivity. 
1  Abbreviation  used in this loafer: ECM,  extracellular  matrix. 
At least four lines of evidence support CD44 involvement 
in tumor development: immunochemical  and RNA blot data 
show that malignant cells express higher levels of CD44 than 
their nonmalignant counterparts (5); CD44/pgp-1 is one of 
a small number of cell surface molecules expressed in tumori- 
genic but not nontumorigenic variants  of the murine thyo 
moma SL12 (16); invasiveness of human bladder carcinoma 
cells has been shown to correlate with the level of expression 
of CD44 (17); and recent studies suggest that high expres- 
sion of CD44 is associated with aggressive behavior and poor 
prognosis of human non-Hodgkin's lymphomas (18). This 
observation is  highlighted by  the  absence  of correlation 
between expression  of the adhesion molecules LFA-1 and 
ICAM-1, which have been implicated in tumor metastasis, 
and clinical evolution of non-Hodgkin's lymphomas (18). Be- 
cause the currently available anti-human CD44 mAbs do not 
distinguish between the two isoforms, immunohistochem- 
ical approaches cannot easily determine whether expression 
of either or both polypeptides correlates with tumor behavior. 
However, the observation that expression of RNA transcripts 
specific for both forms is increased in carcinomas (5, 9) sug- 
gests that both CD44H and CD44E may be associated with 
tumorigenesis. 
Materials and Methods 
Creation of Stable Transfectants.  Namalwa  cells obtained from 
ATCC. The Nawalwa cell line was established  from a human Bur- 
kitt (B cell) lymphoma and secretes small amounts of a mAb (IgM, 
light chain) of unknown specificity  (19). Stable transfectants  were 
created as described (9). Briefly, CD44H and CD44E-containing 
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vector digested with XbaI. The resulting constructs were intro- 
duced into Namalwa cells  by electroporation (400 W960/~F). Elec- 
troporated cells were cultured in RPMI supplemented with 20% 
fetal bovine serum for 48 h following which stable transfectants 
were selected in the presence of 500/~g/ml hygromycin (Sigma 
Chemical Co., St. Louis, MO). Outgrowth of resistant cells was 
observed 4 wk following transfection. Transfectant  were subcloned 
by limiting dilution and tested for surface  expression of the CD44 
isoforms  by indirect immunofluorescence  and immunoprecipitation. 
Immunoprecipitations.  Cells  were metabolically  labeled with 3ss 
cysteine-methionine (Trans-label; ICN, Costa Mesa, CA), in cys- 
teine/methionine-free RPMI supplemented in 5% dialyzed fetal 
bovine serum, overnight and lysed in a Tris-buffered saline solu- 
tion containing  1%  NF-40, 20 mM iodoacetamide and 1 mM 
phenylmethylsulfonylfluoride  (PMSF). After preclearing with mu- 
fine isotype matched immunoglobulin (Cappel, Malvern, PA) and 
protein A sepharose CL-4B (Sigma Chemical Co.) for 4 h, the ly- 
sates were treated with 1-173 mAb and protein A sepharose beads 
overnight. The beads were washed, and the precipitates duted and 
electrophoresed on an 8% acrylamide  gel under reducing  conditions. 
Immunofluorescence.  Transfectants and parental Namalwa cells 
were incubated with mAb 1-173, specific for human CD44 (5), 
or an irrdevant isotype-matched control antibody for 45 rain at 
4~  washed in PBS, incubated with affinity purified fluorescein- 
conjugated  rabbit anti-mouse antibody (Cappel) for 30 min at 4~ 
washed and analyzed on a FCS analyzer (Becton-Dickinson and 
Co., Mountain View, CA). 
For staining tissue sections  with soluble  CD44-Ig chimeras, mu- 
rine frozen tissue sections were incubated with CD44-Ig in PBS 
diluted 1:10 (approximatdy  100/~g/ml)  for 1 h at RT, washed 
in  PBS, incubated  with  an  a~nity-purified  goat  anti-human 
fluorescein-conjugated  antibody (Cappel) for 30 rain at RT, washed, 
and analyzed under a fluorescence microscope, as described (7). 
Injection of Transfectants.  To test for local tumorigenicity, nude 
(Balb/c nu/nu) mice were injected subcutaneously with CD44H, 
CD44E transfectants or parental Namalwa cells. In the initial ex- 
periment, ten animals each were injected subcutaneously  with 1@ 
Namalwa cells, or either of the two transfectants. These experi- 
ments were then repeated by injecting 5 mice each with 106 cells 
of different isolates of each transfectant; two independent CD44H 
transfectant isolates, CD44.5 and CD44.51, and three independent 
CD44E transfectant isolates, CD44HT3,  HT4 or HT6 were in- 
jected. Animals were monitored weekly for visible tumor growth. 
On day 42, some animals were sacrificed  to examine tumors histo- 
logically. Other animals were observed for a total of 90 d. 
To test for metastatic potential, parental cells or each of the two 
transfectants were injected into the tail vein of nude mice. In the 
first set of  experiments, nude mice  were subdivided  into three groups 
of 10 mice. Each group was injected with either CD44H transfec- 
rants, CD44E transfectants or parental Namalwa cells, and each 
animal received 106 cells. In the second set of experiments, each 
animal received 5 x  1@ cells; 11 mice received CD44H transfec- 
tants, 8 mice received  parental Namalwa ceils and 15 mice received 
CD44E transfectants. 
Monitoring of Tumor Growth.  Sera  were obtained from each 
mouse on a weekly basis and human IgM level determined using 
an ELISA assay specific for )~ chain bearing human IgM. Briefly, 
96-weU ELISA plates were coated with 0.5 mg/ml purified goat 
anti-human IgM antibodies (Southern Biotechnology Associates, 
Birmingham, AL) and serum samples were serially diluted. The 
second antibody  was  an af~nity purified alkaline phosphatase- 
conjugated  goat  anti-human  lambda  chain-specific antibody 
(Southern Biotechnology Associates). An affinity-purified human 
IgM was used as a control. 
Histology.  Tissues  were fixed  in formalin, embedded  in paraffin 
and 4-8/~m sections were mounted onto slides and stained with 
hematoxylin-eosin according to standard procedures. 
Adhesion Assays.  96-well  U bottom plates (Microtest III, Falcon 
3911; Becton Dickinson & Co., Lincoln Park, NJ) were coated with 
100  /~g/ml hyaluronate (Sigma Chemical  Co.)  chondroitin-6- 
sulphate (Sigma Chemical Co.) or chondroitin-4-sulphate (Sigma 
Chemical Co.) in PBS overnight at room temperature. Transfec- 
tants and parental cells were radiolabded with 50 p~Ci SlCr (New 
England Nuclear, Boston, MA) for 1 h.  104 cells were added to 
each well and incubated at room temperature. Plates were washed 
4 times with PBS, adherent cells lysed with 100 ~1 of 1% NP-40, 
and bound cpm determined.  All samples were measum:l  in triplicate. 
Comparison of Cellular Growth Rate In Vitro  5 x  104 cells were 
cultured per well in R.PMI medium supplemented with 10% FI~S 
in 96-well flat bottomed microtiter plates (Falcon, Lincoln Park, 
NJ). After 24 h, ceils were pulsed with 1 ~Ci of [3H]thymidine 
for 4 and 24 h. Cells were harvested  with an automatic pH.D. har- 
vester (Cambridge Bioscience, Cambridge, MA) and [3H]thymi- 
dine incorporation was determined. All cultures were done in 
triplicate. 
Production of Soluble CD44-Ig Chimeras.  Creation of soluble 
CD44-immunoglobulin chimeras were described previously (7). 
Briefly, PCR-amplified cDNA sequences encoding the extracel- 
lular domain of CD44H were ligated to expression plasmids con- 
taining genomic sequences encoding human immunoglobulin con- 
stant  regions. Expression plasmids bearing  the  chimeras were 
introduced into COS ceils and supernatants harvested 7-10 d after 
transfection. Typically  1-3 #g/ml of soluble protein were obtained. 
For use in tissue staining, the  soluble protein was purified on 
Trisacryl protein A columns (Pierce Chemical Co., Rockford, IL) 
as described (7). 
Results 
Creation of Stable Transfectants and Assays for A.~nity to Sub- 
strate.  To determine whether expression of either isoform 
of CD44 may influence tumor growth, cDNA clones en- 
coding CD44H and CD44E were stably introduced into Bur- 
kitt lymphoma Namalwa cells (19), which do not constitu- 
tively express CD44.  The CDM8 expression vector (5,  9) 
containing either CD44H or CD44E cDNAs was linearized 
with the restriction endonudease SpeI and ligated to a p205 
plasmid (9) digested with XbaI. p205 contains the Epstein- 
Barr virus EBNA-1  gene, allowing the plasmid to be stably 
maintained in episomal form, and a hygromycin resistance 
gene as a selectable marker (9). CD44Hp205 and CD44Ep205 
were introduced into Nama]wa cells by dectroporation and 
stable transfix-'tants  were selected in the presence of  hygromycin, 
subdoned and tested for surface expression  of CD44 by in- 
direct immunofluorescence and immunoprecipitation (Fig. 1). 
Previous observations suggested that the two CD44 iso- 
forms  display  different  affinities  for  call-surface  bound 
hyaluronate (9). To determine whether the two polypeptides 
differ in their af~nity for ceU-free substrate, transfectants were 
tested for adherence to plastic microtiter wells coated with 
hyaluronate, chondroitin-6-sulphate and chondroitin-4-sul- 
phate.  Only transfectants expressing  CD44H  adhered  to 
hyaluronate-coated wells and, less avidly, to chondroitin-6- 
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and CD44E in stable transfectants as 
assessed by  immunoprecipitation 
(A-C), and indirect immunofluores- 
cence (D and E). Immunoprecipita- 
tion of CD44 from: lane  A: CD44H 
transfectants; lane B: CD44E trans- 
fectants; lane C: parental Namalwa 
cells. Mol wt are indicated  on the left. 
(D): reactivity  with CD44  mAb 1-173 
(5) of  CD44H transfectants  (solid  line), 
compared  to parental cells  (broken  line); 
(E): reactivity  of  CD44E  transfectants 
(solid line) compared to parental cells 
(broken line). Dotted lines  indicate  re- 
activity of transfectants with an un- 
related isotype-matched control an- 
tibody. 
sulphate coated wells (Table 1).  CD44E transfectants  failed 
to display specific adhesion to any of the glycosaminoglycans 
tested. These observations are consistent with earlier findings 
that  CD44H but not CD44E promotes adhesion to lymph 
node  stromal  cells  and  that  the  adhesion  is  mediated  by 
hyaluronate  (9). 
CD44H  Transfectants Promote  While CD44E  Transfectants 
Inhibit  Lymphoma  Growth  in  Nude  Mice.  To  determine 
whether CD44 expression in Namalwa ceils modifies their 
behaviour in vivo,  106 transfectants  expressing either CD44H 
or CD44E, or parental Namalwa cells were injected s.c. into 
three groups of 10 nude mice each. The animals were moni- 
tored weekly for visible tumor growth. Within 7 d, the first 
tumors in animals injected with CD44H transfectants were 
visible. By 42 d, 90% of animals injected with CD44H trans- 
fectants had grossly visible tumors ranging from 0.5 to 2 cm 
in diameter (Fig. 2). In animals injected with parental Namalwa 
cells, visible tumors appeared only on day 28, and only 30% 
of the animals  developed tumors after 70 d  of observation 
(Fig. 3). However, animals which had received CD44E trans- 
fectants displayed no tumor growth even 90 d following in- 
jection. 
Tumor-bearing animals were sacrified between days 42 and 
70 and the tumors excised. Tumors were typically encapsu- 
lated and displayed no infiltration of underlying muscle tissue. 
Histologic examination  revealed large cell lymphomas,  but 
only CD44  transfectant-derived  tumors reacted with  anti- 
CD44 antibodies (data not shown), suggesting that parental 
cell-derived tumor  growth was not  associated with induc- 
tion  of CD44  expression. 
Because transfectant-assodated  tumor development may have 
been due to intrinsic properties of the particular  Namalwa 
cell clones rather than CD44 expression,  the initial experi- 
ments were repeated with two independent transfectant iso- 
lates expressing CD44H (CD44.5 and CD44.51),  three in- 
dependent isolates expressing CD44E (HT3, HT4 and HT6) 
and parental cells.  The clones were selected on the basis of 
a comparable level of expression of the CD44 polypeptides 
and five mice were injected with 106 cells derived from each 
isolate or the parental cell line.  None of the CD44E transfec- 
tants  developed  tumors  while  both  CD44H  transfectants 
formed tumors in 80% of animals confirming the initial ob- 
servations.  Because Namalwa ceils secrete detectable amounts 
of IgM (19), tumor growth could be conveniently monitored 
by weekly measurements of human IgM levels in the murine 
sera. Human IgM levels were found to correlate with tumor 
size in both transfectant-  and parental  cell-derived tumors, 
and IgM production by Namalwa cells and transfectants,  in 
vitro, was found to be comparable (data not shown). Results 
obtained by monitoring  human IgM levels in mice injected 
Table  1.  Binding of Namalwa CD44(H) but not Namalwa CD44(E) to Hyaluronate and Chondroitin Sulfate A 
Namalwa CD44(E)  Namalwa  CD44(H)  Namalwa 
cpm bound 
Background  2,333  •  176  4,500  _+  290  4,000  _+  120 
Hyaluronate  2,500  •  200  17,000  _+  198  5,200  •  456 
Chon.  Sulf. A  3,000  •  78  11,000  •  389  5,500  •  349 
Chon.  Sulf. C  3,000  •  34  5,590  •  467  5,900  _+  400 
Comparison of adhesion of transfectants and parental Namalwa cells to substrate. The numbers represent the average of the triplicate and the standard 
error is <5%.  The total SlCr incorporation for the three cell lines was comparable. 
861  Sy et al. 1 O0 
to  ~  Namawal ~.  -  = 
a  80,  '" ￿9  CD44(H)  /  (9/I0) 
E  ;  CD44(Ey 
J~ 
60' 
.E_  40 
20 
o  ~-  -  ;  J,  (O/lO) 
o  20  40  6o  80 
Days after tumor injection 
Figure 3.  Rate  of tumor development in animals injected subcutane- 
ously with  CD44H,  CD44E transfectants and parental Namalwa calls. 
The number of animals injected with each ceU type and the fraction of 
animals developing tumors in each group are indicated. 
Figure 2.  Tumors  obtained in nude mice 42 d post s.c. injection. (.4): 
representative mice injected with CD44H transfectants (left) (9 out of 10 
mice developed tumors of similar size), and parental Namalwa cells (righ  0 
(3 out of 10 mice developed  similar tumors) are shown. (B): Excised  tumors 
from a CD44H recipient (left) and a parental cell recipient (right). 
subcutaneously with transfectants derived from done CD44.51 
and  parental  Namalwa cells are shown in Table 2. 
CD44H and CD44E  Transfectants and Parental Cells Have 
Comparable Growth Characteristics  In Vitra  To establish  tumor- 
derived CD44H cell lines,  tumors were excised and cells teased 
from the tumor mass and grown in in vitro culture in the 
presence of hygromycin. Cultured tumor-derived cells reacted 
with mAbs directed against human MHC  class I  and class 
II  molecules,  confirming  that  the  tumors were  of human 
origin, and surface expression of CD44 in tumor-derived cells 
was  comparable  to  that  in  CD44  transfectants  (data  not 
shown). Proliferation assays revealed  that parental  Namalwa 
cells,  CD44H  and  CD44E  transfectants  as  well  as  CD44 
tumor-derived cells had the same proliferation rate in vitro 
(Table 3). This finding eliminated the possibility that the differ- 
ence in in vivo growth between CD44 transfectant  and pa- 
rental cell tumors was a reflection of different baseline prolifer- 
ation rates between the cell lines. 
Glycosaminoglycan-coated Surfaces Do not Promote CD44H 
Transfectant Growth In Vitra  To determine whether the en- 
hanced growth of CD44H tumors was the result of CD44- 
hyaluronate or CD44-chondroitin sulfate interaction, CD44H 
transfectants and parental cells were cultured in the presence 
of  various  concentrations  of  hyaluronate  or  grown  on 
hyaluronate or chondroitin-6-sulphate-coated  plates.  How- 
ever,  neither presence of hyaluronate in the cell cultures nor 
the growth of cells on hyaluronate or chondroitin sulphate 
coated-plates revealed any significant modification in prolifer- 
Table  2.  Concentration of Human IgM in the Serum of Nude Mice Injected with Namalwa or Namalwa CD44 (1-1).51 
Namalwa  Namalwa CD44 (H).51 
d  after  injection  d  after injection 
Animals  14  28  35  42  49  14  28  35  42  49 
mg/ml 
1  -  0.6  5  12  (S) 
2  -  0.5  10  18  (S) 
3  -  0.2  8  0.2  0.5  6  i8 
4  -  0.3  3  11 
5 
Comparison of human IgM levels in nude mice injected with Namalwa cells or CD44.51 (CD44H) transfectants. (-: not detectable; s: sacrificed). 
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Figure 4.  Rate of tumor devel- 
opment in animals having received 
CD44 transfectants  or parental cells 
intravenously. Results obtained in 
animals injected with 106 and 5  x 
10  ~ cells are  shown  on  left  and 
right, respectively.  The number of 
animals in each group is shown in 
brackets. Tumor  growth was  as- 
sessed  by human IgM concentration 
in  the  serum  of each individual 
mouse and verified  by histologic ex- 
amination. 
ation of either transfectant or parental'cells (data not shown). 
This observation suggests that the presence of hyaluronate 
or chondroitin  sulphate  alone is  not  su~cient  to  trigger 
proliferation of CD44H  expressing cells in vitro. 
CD44H-transfectant Tumor Growth In Vivo Is not Due to Greater 
Resistance to NK Cytotoxicity.  Several tumor cell lines which 
express the hyaluronate receptor form a pericellular coat of 
hyaluronate which may confer protection from T cell or NK 
cell-mediated cytotoxicity (11). To rule out the possibility that 
growth of CD44 tumors was due to protection against NK- 
mediated cytotoxicity, transfectants and parental cells were 
cocultured with nude mouse spleen cells but no significant 
cytolysis of either target was observed (data not shown). 
CD44H Induces a Higher Metastatic Potential in Lymphoma 
Cells, While CD44E Reduces Metastatk Proclivity.  The ob- 
servation that CD44H  promotes lymphoma growth in s.c. 
tissues raised the possibility that CD44 polypeptides may also 
play a role in determining the tissue distribution and growth 
rate of metastatic tumors. The frequency of tumor develop- 
ment in intravenously injected animals was consistent with 
that observed as a result of s.c. injections and correlated with 
the number of cells injected (Fig.  4).  Tumors developed in 
80% and 100% of animals receiving CD44H transfectants 
in experiments 1 (106 cells) and 2  (5  x  106 cells),  respec- 
tively.  Animals injected with parental Namalwa cells  and 
CD44E transfectants developed detectable tumors respectively 
in 40%  and 20%  of cases in experiment 1,  and 60%  and 
33% of cases in experiment 2 (Fig.  4). The rapidity of de- 
tectable tumor appearance, as assessed by measurement of 
human IgM levels in murine serum, was consistent with tumor 
development  in  s.c. tissues.  The  first  CD44H-expressing 
tumors were detected at days 20 and 14 in experiments 1 and 
2, respectively, while the first parental cell tumors appeared 
at days 55 and 21, respectively. In the few cases of CD44E- 
derived tumors, the first detectable growth occurred only 75 
and 42 d  post injection, respectively (Fig.  4). 
However, with the exception of renal tissue,  where only 
CD44H transfectants formed tumors, tissue distribution of 
Table  3.  In  Vitro Proliferation of Namalwa, Namalwa 
CD44(H), Namalwa CD44(E) and Three Different Tumor-derived 
Namalwa-CD-44(H) Cell Lines 
[3H]Thymidine incorporation 
4h  24h 
Namalwa 
Namalwa CD44  (H) 
Namalwa CD44  (E) 
CD44.(H)N  2 
CD44.(H)N  3 
CD44.(H)N  4 
62,350  •  4,100 
57,000  •  3,400 
80,100  •  5,100 
82,000  •  320 
73,000  •  4,200 
97,000  •  543 
295,300  _+  12,000 
210,000  +  5,700 
340,000  +  3,140 
280,000  _+  1,100 
276,000  +_  987 
273,400  _+  1,300 
Comparison of in vitro growth rates, expressed as [3H]thymidine incor- 
poration, between parental Namalwa cells and transfectants. All cultures 
were done in triplicate and the numbers presented are the average of the 
radioactive thymidine incorporation in each triplicate. Standard errors are 
indicated ( + / - ). CD44.HNg,  CD44H.N3  and CD44H.N4 are cell lines 
derived from  tumors  excised from  three  different mice injected with 
CD44H transfectants. 
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Table  4.  Tissue  Distribution of Metastases Derived  from 
CD44H and E  Transfectants and Parental Namalwa Cells 
Number of animals with metastases 
Tissue  CD44H  (19/21)  Namalwa (9/18)  CD44E  (5/25) 
marrow  17  5  2 
gut  7  5  3 
kidney  8  0  0 
pancreas  3  4  2 
liver  1  0  0 
spleen  1  0  0 
muscle  5  3  0 
adrenal  3  0  0 
peritoneum  5  3  0 
Tissue distribution  of metastases derived from CD44H and E transfec- 
tants and parental Namalwa cells. Cumulative results from experiments 
1 (10  + cells) and 2 (5  x  106 cells) are shown.  The fraction of injected 
animals which developed  metastases in each group is indicated in brackets. Figure 5.  Histology of CD44H tumor metastases; all tissue examined by light microscopy are stained with hematoxylin  and eosin. (A) low power 
(x64) magnification  of bone marrow metastases showing normal  marrow (bottom arrow) and marrow replaced by tumor cells (top arrow); (B) Higher 
power magnification of tumor cells in (A) showing monomorphic tumor appearance (x 128); (C) Metastatic growth in adrenal medulla (arrows),  while 
the cortex is spared ( x 128); (D) tumor infiltration of intestinal submucosa (x 64); (E) Higher power (x 128) magnification of submucosal tumor infiltra- 
tion showing sparing of muscle layers (arrows); (F) Fluorescent micrograph  showing intestinal  submucosal reactivity with CD44-Ig (x 128); (G) Low 
power magnification  of renal medulla metastasis (￿  (H) Higher power magnification  (x128) of metastasis in (G) showing tumor cell infiltration 
in the interstitium  between renal tubules; (/) CD44-1g reactivity with renal medulla interstitium,  showing a pattern  reminiscent of tumor cell infiltra- 
tion (x 128). 
metastases was not significantly  different between CD44H 
and parental cell-derived  tumors (Table 4).  Both cell types 
preferentially  formed metastases in the bone marrow, with 
local invasion  and destruction of muscle, bone, and neural 
tissue (Fig. 5). Metastases were also commonly found in the 
gut submucosa (Fig.  5) and pancreas (data not shown). In- 
terestingly, in renal  tissue,  tumor growth was observed in 
the medullary and papillary interstitium where concentra- 
tions of hyaluronate, and consequently reactivity with soluble 
CD44, appear  to be the highest (Fig.  5) (7, 20).  Similarly, 
metastases in the gastrointestinal tract developed within the 
submucosa (Fig.  5) which is strongly reactive with soluble 
CD44 (Fig.  5) (7).  In the only case of liver metastasis in a 
CD44H-transfectant-injected  animal, tumor developed around 
centrilobular veins and beneath the capsule,  the only two 
regions which react with soluble CD44 (7) (data n6t shown). 
Discussion 
Our results demonstrate that expression of CD44H in a 
B cell lymphoma enhances both primary and secondary tumor 
growth in nude mice. However, the observation that 30-60% 
of parental cell recipients also developed primary and metastatic 
tumors after a longer latency, suggests that CD44H expres- 
sion in lymphoma cells may promote the initiation of tumor 
growth but is not essential for tumor development. Animals 
injected subcutaneously or intravenously with cells expressing 
the epithelial isoform of CD44,  on the other hand, rarely 
developed tumors, suggesting that expression of CD44E may 
interfere with lymphoma growth in vivo. 
With the exception of renal metastases, which were caused 
exclusively by CD44H transfectants,  the tissue distribution 
of transfectant and parental cell-derived metastases was similar. 
These observations are consistent with earlier suggestions that 
expression of CD44H does not correlate with the metastatic 
pattern of human lymphomas (21, 22) implying that CD44H 
may not  distinguish specific endothelial cell  receptors  in 
different organs.  Rather,  CD44H  may enhance secondary 
tumor growth by facilitating interactions between tumor cells 
and host tissues. The pronounced tropism of CD44H trans- 
fectants  to the bone marrow may be explained by observa- 
tions that CD44H expression in hematopoietic cells may play 
an important role in their interaction with the medullary 
microenvironment (23).  It is noteworthy that each of the 
tissues in which rapid CD44H tumor development occurred 
has an elevated content of hyaluronate and reacts  strongly 
with soluble CD44 (7, 20), suggesting that CD44-hyaluronate 
864  Distinct Effects of Two CD44 Isoforms on Tumor Growth In Vivo interaction may be directly responsible for enhancement  of 
tumor  growth in vivo. 
The difference in tumor growth promoting effects between 
the two CD44 isoforms correlates with the difference in their 
affinity for  surface-bound  hyaluronate.  The  failure  of hy- 
aluronate to enhance CD44 transfectant proliferation in vitro 
may therefore not reflect its in vivo role. Hyaluronate is gener- 
ally thought to promote cell motility by creating a low resis- 
tance, highly hydrated matrix.  However, a substantial por- 
tion of hyaluronate is bound to stromal cells and various ECM 
molecules, including link proteins  and proteoglycans (24), 
and may therefore provide a molecular bridge which facili- 
tates adhesion of CD44H expressing malignant cells to host 
tissue stromal cells and ECM. The resulting interactions may 
stimulate tumor development in several ways. First, immobili- 
zation of tumor cells can provide loci for subsequent colony 
formation; second, tumor cell-stromal cell interaction has been 
shown to generate the production of growth and angiogenic 
factors which promote tumor growth (25); and third, malig- 
nant cells may gain better access to growth factors sequestered 
by ECM proteoglycans (26). However, CD44H may recog- 
nize additional  ligands  in host  tissues which may directly 
stimulate tumor cell proliferation.  The cytoplasmic domain 
of CD44H has been shown to interact with cytoskeletal pro- 
teins (27) and may provide a pathway for intracellular signal 
transmission. This suggestion is supported by recent evidence 
that crosslinking of CD44 is comitogenic for T lymphocytes 
(2)  and may induce monocytes to  secrete cytokines (28). 
Because both forms of CD44 have an identical cytoplasmic 
domain,  the observed differences in their tumor promoting 
properties in lymphoma cells are most likely due to the pres- 
ence of the additional stretch of 134 residues in the extracel- 
lular domain of CD44E.  In normal epithelial cells,  expres- 
sion of CD44H or CD44E may reflect the requirement  for 
different  types of interaction  between a given cell and its 
neighbors.  One example may be provided by pluristratified 
epithelia, where apical,  intermediate and basal cells each in- 
teract with a different milieu.  Tumors derived from epithe- 
lial cells expressing one or the other of the isoforms are there- 
fore likely to display differences in affinity for different types 
of microenvironment which may condition their growth and 
development. 
While  this  work was in progress,  Gunthert  et al.  (29) 
showed that rat carcinoma cell lines which do not metasta- 
size can acquire metastatic properties upon transfection with 
the rat homologue of CD44E. One possible explanation for 
the apparent discrepancy between these observations and ours 
may be that CD44E confers different tumorigenic properties 
to epithelial and lymphoid cells. However, in the experiments 
of Gunthert et al. (29) the transfected tumor cells constitu- 
tively expressed the rat homologue of CD44H. The enhanced 
metastatic potential  of transfected cells  may therefore have 
been related in part to coexpression of both CD44 isoforms. 
The present observations suggest that CD44H participates 
in determination of the rate of both primary and metastatic 
lymphoid tumor growth. Expression of CD44H may there- 
fore constitute a major prognostic factor in human hemato- 
poietic malignancies. 
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